logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5529.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5529.produseast1
World Hepatitis Day 2022 | Collections | MSF Science Portal
World Hepatitis Day 2022

World Hepatitis Day 2022

Each year hundreds of millions of people suffer from chronic or acute liver disease caused by hepatitis viruses, and over one million die. To mark World Hepatitis Day (July 28th) we bring you a selection of MSF research exploring how to better prevent, identify and treat hepatitis infection in lower-income countries and emergency contexts where the burden is heaviest.

For example, in a South Sudanese camp for displaced people—a type of setting where poor sanitation and water quality regularly lead to hepatitis E outbreaks—MSF and the Ministry of Health (MoH) are conducting the world’s first reactive vaccination campaign against this disease, and evaluating the process and outcomes.

In Cambodia, MSF and MoH collaborators found that a simplified community-based model of care for hepatitis C was safe and highly effective in diagnosing patients and in curing them with new antiviral drugs. It was also cost-effective, according to studies in several countries and patient populations. And these new drugs were safe and effective even in patients also being treated for drug-resistant tuberculosis.

Collection Content

Journal Article
|
Letter

The first reactive vaccination campaign against hepatitis E

Ciglenecki I, Rumunu J, Wamala JF, Nkemenang P, Duncker J,  et al.
2022-08-01 • Lancet Infectious Diseases
2022-08-01 • Lancet Infectious Diseases
Conference Material
|
Video

The first reactive mass vaccination campaign against Hepatitis E in Bentiu, South Sudan

Nesbitt RC
2022-06-21 • Epicentre Scientific Day Paris 2022
2022-06-21 • Epicentre Scientific Day Paris 2022
Journal Article
|
Research

Integrating hepatitis C treatment into multidrug-resistant TB care

Kirakosyan O, Melikyan N, Falcao J, Khachatryan N, Atshemyan H,  et al.
2022-06-21 • Public Health Action
2022-06-21 • Public Health Action
BACKGROUND
Direct-acting antivirals (DAAs) are not widely used for patients with chronic hepatitis C virus (HCV) infection and multidrug- or rifampicin-resistant TB (MDR/RR-TB). We d...
Journal Article
|
Research

Prevention of mother-to-child transmission of hepatitis B virus in antenatal care and maternity services, Mozambique

Loarec A, Nguyen AP, Chissano M, Madeira N, Rusch B,  et al.
2021-12-02 • Bulletin of the World Health Organization
2021-12-02 • Bulletin of the World Health Organization
OBJECTIVE
To pilot an intervention on the prevention of mother-to-child transmission (PMTCT) of hepatitis B virus (HBV) in an antenatal care and maternity unit in Maputo, Mozambique,...
Journal Article
|
Research

Decentralised hepatitis C testing and treatment in rural Cambodia: evaluation of a simplified service model integrated in an existing public health system

Zhang M, O'Keefe D, Craig J, Samley K, Bunreth V,  et al.
2021-03-19 • Lancet Gastroenterology and Hepatology
2021-03-19 • Lancet Gastroenterology and Hepatology
BACKGROUND
Direct-acting antiviral treatment for hepatitis C virus (HCV) has provided the opportunity for simplified models of care delivered in decentralised settings by non-special...
Journal Article
|
Research

Hepatitis C viraemic and seroprevalence and risk factors for positivity in Northwest Cambodia: a household cross-sectional serosurvey

Lynch E, Falq G, Sun C, Bunchhoeung PDT, Huerga H,  et al.
2021-02-26 • BMC Infectious Diseases
2021-02-26 • BMC Infectious Diseases
BACKGROUND
Despite a dramatic reduction in HCV drug costs and simplified models of care, many countries lack important information on prevalence and risk factors to structure effecti...
Journal Article
|
Research

Concomitant treatment of chronic hepatitis C with direct-acting antivirals and multidrug-resistant tuberculosis is effective and safe

Melikyan N, Huerga H, Atshemyan H, Kirakosyan O, Sargsyants N,  et al.
2021-01-04 • Open Forum Infectious Diseases
2021-01-04 • Open Forum Infectious Diseases
We assessed effectiveness and safety of concomitant chronic hepatitis C virus (HCV) treatment with direct-acting antivirals (DAAs) and multidrug-resistant tuberculosis (MDR-TB). Of 322 M...
Journal Article
|
Research

Cost-effectiveness of screening and treatment using direct-acting antivirals for chronic Hepatitis C virus in a primary care setting in Karachi, Pakistan

Mafirakureva N, Lim AG, Khalid GG, Aslam K, Campbell L,  et al.
2020-11-04 • Journal of Viral Hepatitis
2020-11-04 • Journal of Viral Hepatitis
Despite the availability of effective direct-acting antiviral (DAA) treatments for Hepatitis C virus (HCV) infection, many people remain undiagnosed and untreated. We assessed the cost-e...
Journal Article
|
Research

An intensive model of care for hepatitis C virus screening and treatment with direct-acting antivirals in people who inject drugs in Nairobi, Kenya: a model-based cost-effectiveness analysis

Mafirakureva N, Stone J, Fraser H, Nzomukunda Y, Maina A,  et al.
2020-06-29 • Society
2020-06-29 • Society
BACKGROUND AND AIMS
Hepatitis C virus (HCV) treatment is essential for eliminating HCV in people who inject drugs (PWID), but has limited coverage in resource-limited settings. We me...
Journal Article
|
Research

Cost and cost-effectiveness of a simplified treatment model with direct-acting antivirals for chronic hepatitis C in Cambodia

Walker JG, Mafirakureva N, Iwamoto M, Campbell L, Kim CS,  et al.
2020-05-31 • Liver International
2020-05-31 • Liver International
BACKGROUND & AIMS
In 2016, Médecins Sans Frontières established the first general population Hepatitis C virus (HCV) screening and treatment site in Cambodia, offering free direct-ac...
Conference Material
|
Poster

Outcomes of hepatitis C treatment in vulnerable populations co-infected with HIV and hepatitis C: Programme description, Manipur, India

Himanshu M, Lin Oo W, Cavalheiro AP, Mesic A, Shougrakpam J,  et al.
2020-05-20 • MSF Scientific Days International 2020
2020-05-20 • MSF Scientific Days International 2020

See more collections

World NTD Day
World NTD Day

Neglected tropical diseases (NTDs) impact nearly 1.7 billion people each year, causing serious illness or lifelong disability among many—often leading to stigma and exclusion—and killing an estimated 200,000. The vast majority of sufferers live in the world’s poorest countries.


The World Health Organization’s NTD roadmap 2021-2030 aims to address 20 tropical diseases through prevention, control, elimination, and/or eradication. But despite some progress, reaching all its targets will take better, far more accessible diagnostics and treatments along with more robust strategies, political commitment and resources.


To mark World NTD Day, this collection spotlights work by MSF and collaborators on improving approaches to snakebite envenoming, kala azar and noma. One study presents an innovative artificial intelligence-based snakebite diagnostic tool, while others evaluate shorter, less toxic drug regimens or different models of care. Several commentaries advocate for national/regional strategies adapted to contexts ranging from remote villages to active conflict zones. Another crucial factor is the climate crisis, which is intensifying the transmission and geographic spread of many NTDs.

MSF logo
Advancing Research to Improve NTD Treatments in Children by S...

Dr. Saschveen Singh is a tropical infectious disease advisor for MSF. Read more of MSF's recent work on neglected tropical diseases in pediatric populations, and of Dr. Singh's work at MSF.

MSF Science Portal
MSF Science Portal

While Médecins Sans Frontières (MSF) is known mostly for providing direct medical aid to people affected by conflict, epidemics, disasters, or exclusion from health services, we also conduct research aimed at improving patient care and advocating for evidence-based policy and practices. To this end we conduct hundreds of research studies each year, publish extensively in peer-reviewed journals, and present our findings at scientific conferences around the world, including several annual MSF-organized events.


With the MSF Science Portal we introduce a new platform that aims to be a « one-stop shop » for content related to this work, so that users anywhere can easily find, browse, access, share and use the knowledge our research generates. Alongside frequent updates of new publications, conference materials, reports and featured content, we will continue to develop this site and to expand its range of content. To learn more about the Portal and what it offers, check out the short videos and slide presentation in this collection.

View All Collections